Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest www.briantempest.com Pharmaceuticals.

Slides:



Advertisements
Similar presentations
Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs Experience with Generic drugs Cecile H Miles Head of Western Europe Division.
Advertisements

CIPLA LTD Analyst Report By Siddharth Ghaisas. WHO IS CIPLA & WHAT DO THEY DO? WHO WHO - The Chemical, Industrial & Pharmaceutical Laboratories; - Founded.
December 2010 Economic Overview and Outlook Scottish Supply Chain Conference September 2012 Kenny Richmond Scottish Enterprise.
Hale & Tempest Exploring the Structural Changes in the Global Pharmaceutical Marketplace: an India-China Emerging World Webcast Dr. Brian W Tempest
Hale & Tempest The Global Pharmaceutical Industry (MNC & Generic) in Transition Dr. Brian W Tempest The Global Generic Summit – Barcelona,
Dun & Bradstreet The most trusted source in business insight April 21, 2008 Qatar.
Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest UK 18,19,20 March 2014.
Hale & Tempest Understanding the Strategies Big Pharma are Developing to win in the Global Generics Market Dr. Brian W Tempest Istanbul,
Views on the Generics Market Dr Brian Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories, Delhi, India EGA Conference Istanbul,
Hale & Tempest Global Pharma 2014 Dr. Brian W Tempest Mumbai August 2014.
Shortage of Natural Resources The Scientific Innovative Power coming from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board.
Singapore Market Presentation Pack SINGAPORE TEAM Web: ukinsingapore.fco.gov.uk/ukti Contact:
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Industry Trends and Tools for Generic Product Selection KATE KUHRT SHANGHAI JUNE 19-21, 2007.
Critical Success Factors for the Korean Generic and API Industry in a post FTA Environment DAVID HARDING SEOUL JUNE 28-29, 2007.
Pharmaceuticals before and after TRIPS Sudip Chaudhuri Professor of Economics Indian Institute of Management Calcutta BRICS Workshop, Aalborg February,
© economiesuisse,, Challenges for Switzerland‘s Foreign Trade Policy Gerold Bührer, Chairman 36th Annual General Meeting 2010 ARAB-SWISS CHAMBER OF COMMERCE.
Hale & Tempest Strategic Pharma Issues Dr. Brian W Tempest Mumbai, India May 2013.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Hale & Tempest Exploring the Structural Changes in the Global Pharmaceutical Marketplace Dr. Brian W Tempest 9 th Annual Global Generic.
Hale & Tempest India Biotech Briefing Dr. Brian W Tempest IBIZ Conference, NHS Expo Excel London UK 9 March 2011.
The New Economic Landscape Brian W Tempest CEO & Managing Director Ranbaxy Laboratories Limited, India The Pharmaceutical Industry in the 21 st Century.
Hale & Tempest The Sustainability of Generics Dr. Brian W Tempest Centre for Doctoral Training in Healthcare, University of Oxford,
Hale & Tempest Distribution, OTC & CRAMS Chesapeake Dr. Brian W Tempest UK March 2014.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Hale & Tempest Global Pharma 2014 Dr. Brian W Tempest Mumbai August 2014.
Hale & Tempest Moving Beyond the Commodity Market: What Future is there in added Value Generics, Niche Products and Biosimilars? Dr. Brian W Tempest
Hale & Tempest Inhalation Drug Delivery Conference Dr. Brian W Tempest CpHI Ramada Hotel, Berlin, Germany 11 September 2013.
Global Medical Membrane Market: Industry Analysis, Trend and Growth, by Future Market Insights
Partners in Globalisation UK Trade & Investment British Business Group in Mumbai & Pune Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the.
Reflections on the Global Generic Pharmaceuticals Market place Dr. Brian W Tempest CII Pharma Summit Mumbai Thursday November 1 st.
Hale & Tempest India UKIBC Briefing Dr. Brian W Tempest UK India Business Council Manchester 10 March 2011.
TECHNOLOGICAL CHANGES IN GLOBAL ECONOMY PRESENTED BY: BIJAY SHARMA SECTION: A PGDM 1 st SEM.
Global Erythritol Market Share, Global Trends, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2015.
Hale & Tempest Bangladesh Pharma Industry Dr. Brian W Tempest UNCTAD Investment Policy Review of Bangladesh United Nations Palais.
Hale & Tempest Exploring the Structural Changes in the Global Pharmaceutical Marketplace Dr. Brian W Tempest MAPE Fund Managers Conference.
Hale & Tempest A View from India Dr. Brian W Tempest Opinion Formers’ Conference on Intellectual Property for Better Health Wellcome.
Hale & Tempest Strategic Pharma Issues Dr. Brian W Tempest Mumbai, India January 2013.
Hale & Tempest How to provide affordable medicines in today’s competitive Global Market Dr. Brian W Tempest
Hale & Tempest Mergers, Acquisitions & Alliances in Emerging Markets Dr. Brian W Tempest Generics & Biosimilars, CpHI Conference Istanbul,
Hale & Tempest The Sustainability of the Generics Industry – rethinking the future Dr. Brian W Tempest World Generics Congress, London,
Hale & Tempest Global Generics & Companies Chesapeake Dr. Brian W Tempest UK March 2014.
Hale & Tempest Bangladesh Pharma Industry Dr. Brian W Tempest UNCTAD Investment Policy Review of Bangladesh United Nations Palais.
Hale & Tempest Indian Drug Discovery Dr. Brian W Tempest Asia Pacific Technology Network Tuesday 3 April 2012.
Hale & Tempest Mergers, Acquisitions & Alliances in Emerging Markets Dr. Brian W Tempest Generics & Biosimilars, CpHI Conference Istanbul,
Hale & Tempest Doing Business in Russia - the View from Overseas Dr. Brian W Tempest CpHI St Petersburg, Russia 17 April 2014.
Hale & Tempest How a Major Indian Generic Company went Global Dr. Brian W Tempest Shanghai, China 18 November 2011.
GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.
India – The Pharma Advantage Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Tokyo –
Hale & Tempest Consultation of Experts to discuss the WHO role in facilitating access to quality, affordable biotherapeutics (monoclonal antibodies & biosimilars.
DIVERSITY IN THE CONVERGENCE PROCESS OF ACCESSION COUNTRIES Urmas Varblane University of Tartu ASIAN CENTURY? – THE GROWING ROLE OF ASIA Urmas Varblane,
MarketsandMarkets Presents Global In-Vitro Diagnostic (IVD) Market Expected to Reach $64 Billion by 2016
Hale & Tempest Patents & Health Dr. Brian W Tempest Seminar on the Relationship between Patent Systems and the Availability of Medicines.
Hale & Tempest Biosimilars in Developing Countries: Key Issues Dr. Brian W Tempest Editor, Journal of Generic Medicines Bangladesh.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024 Citric Acid Industry Share,
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.
Cell Line Development Market to witness growth of 13% from 2016 to 2023
Address to the IEEE Region 10 Leadership IEEE Region 10 Meeting
Biosimilars in Developing Countries: Key Issues
CIPS GLOBAL REACH STRATEGY
India: A Phoenix Reborn
Chemical Industry in Europe – Trends
European Chemical Industry: Cefic Chemicals Trends Report (CTR)
Intl Director of Campaigns Director of Policy & External Affairs
Middle East ____________
INFORMATION AND DIGITAL ECONOMICS(5ECON007W)
Religare Health Insurance Company Limited
Presentation transcript:

Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest www.briantempest.com Pharmaceuticals & Global Health Sussex University Conference Centre , Brighton, UK 19 July 2013

Dr Brian Tempest advises Companies, Banks, High Net Worth Individuals and Investment Funds on their Strategy in the Emerging World based on his wide experience in China, Japan, South East Asia and India where he has lived for the last decade. Brian has worked for Ranbaxy Laboratories since 1995 holding the position of Managing Director and Chief Executive Officer until 2005. He was then Chief Mentor and Non Executive Director until 2008 when he retired. He is one of the few westerners to have led a Sensex Nifty 50 Indian blue Chip MNC and as a result has a valuable insight into India. Brian has also worked for Glaxo as Regional Director Far East and Regional Director Middle East & Africa from 1985 to 1992. Brian has worked in the Pharmaceutical Industry for the last 41 years and has managed Healthcare businesses in North America, South America, Europe, Africa, Middle East, Australasia, China, Japan and India. He has also led many sessions at Investor Meetings held around the world. He is now Independent Chairman of Religare Capital Markets PLC , a Non Executive Director of Fortis Healthcare the leading Asian Healthcare Company, a Non Executive Director of SRL the largest Indian Diagnostic Company and a Non Executive Director of Glenmark Pharmaceuticals. He is a member of the SCRIP Global awards panel and is on the Editorial Board of the Journal of Generic Medicines. Brian speaks at global conferences and more information on these presentations can be found on his website www.briantempest.com. Brian has a PhD in Polymer Chemistry from Lancaster University in 1971 and in 2009 he became Chairman of the Advisory Board for the Lancaster University Management School, UK. He is a Fellow of the Royal Society of Medicine and a Fellow of the Royal Society of Chemistry and is a Chartered Chemist. He is now Chairman and Senior Partner of Hale & Tempest Co Ltd

Healthcare costs versus GDP & Wages

Everybody Concerned about Health Costs

Increasing Generics & Biosimilars

A Slide from a UK Headhunter

Pharma in Crisis Source: Pharmatimes February 2013

Generics versus Big Pharma

Patent Cliff to 2018 source: Evaluate Pharma, Sandoz

Top 25 Global Generic Companies Source: Generics Bulletin 10 June 2011

Products Going Off Patent in 2015 $33b Source: Evaluate Pharma 14 February 2013

The Teva Future – Standing Still Source: RBC Capital 12 December 2012

Global footprint of Watson/Actavis – excluding most of the developing world

Indian Generic Cos continue to grow Source: Pharmatimes World News Feb 5 2013 Many Indian Companies in 2013 showing a sales growth of >20% Indian Pharma Exports 2008-2012 around the World have shown a %CGR of +19% in sales New Product Pipeline in USA ANDAs shows approvals from India in 2012 was 37% with 178 out of a total of 476 and in 2011 33% with 144 out of 431 New ANDA filings of ANDAs in the USA from India indicate 51% in 2011 and 49% in 2010

India’s First Compulsory Licence after 3 years at a high price Source : Economic Times 13 March 2012

More CLs on the way in India Source: 29 March 2013

India Patent dismissed for Evergreening Source: Financial Express 2 April 2013

Anti Cancer Drugs At Delhi Airport Source: New Delhi Airport 28 March 2013

But Indian Price Cuts source: Hindustan Times 20 June 2013

Aggressive EU-India Bilateral FTA Source: ET 27 March 2013

The Future of IP? In 2012 Big pharma had the best NCE year since 1997 There are $230b sales going off patent in 2013-2018 but only half will be replaced by generics owing to biologics Big Pharma is finding the BRICS markets tough More CLs likely from the BRICS countries owing to evergreening or a very high price limiting access Do all patents need to be 20 years? The first USA patent law in 1790 was for 14 years. What is the point of a patent if only the rich can use it?

Thank You brian.tempest@clara.co.uk www.briantempest.com